The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial

Abstract This open-label phase II trial (NCT04542837) aimed to evaluate the efficacy and safety of KN046 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC), and explore the potential response biomarkers. Participants received KN046 5 mg/kg every 3 weeks and lenvatinib...

Full description

Saved in:

Bibliographic Details
Main Authors:	Da Xu, Hongwei Wang, Quan Bao, Kemin Jin, Ming Liu, Wei Liu, Xiaoluan Yan, Lijun Wang, Yanqiao Zhang, Guangyu Wang, Yue Ma, Zhigang Ma, Chunhui Zhang, Jiebing Tang, Sha Wang, Jiaohui Pang, Ting Xu, Kun Wang, Baocai Xing
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-02-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-025-56537-y
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study
by: Dan Liu, et al.
Published: (2025-03-01)

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)

Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib
by: E. B. Vasilyeva, et al.
Published: (2024-06-01)

Binary Nonlinearization for AKNS-KN Coupling System
by: Xiangrong Wang, et al.
Published: (2014-01-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01)

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01)

The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis
by: Wei Zhang, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective
by: Brandon M. Meyers, et al.
Published: (2021-01-01)

Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases
by: Xiaolong Liu, et al.
Published: (2025-12-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
by: Jin M, et al.
Published: (2024-11-01)

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma
by: Lichang Huang, et al.
Published: (2025-05-01)

Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study
by: Yitao Zheng, et al.
Published: (2025-07-01)

RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2025-05-01)

0.46 Terahertz wave irradiation inhibit transcription reaction in liposomes
by: Gakushi Tsuji, et al.
Published: (2025-05-01)

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
by: Haihong Zhu, et al.
Published: (2024-07-01)

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)

Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial
by: Jianli Ma, et al.
Published: (2025-04-01)

Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors
by: Wei SM, et al.
Published: (2025-06-01)

Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Targeted therapies and immunotherapies for unresectable cholangiocarcinoma
by: Shengbai Xue, et al.
Published: (2025-08-01)

The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
by: Hongxin Li, et al.
Published: (2024-11-01)

Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma
by: Junying Wang, et al.
Published: (2025-06-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
by: Yaofei Jiang, et al.
Published: (2025-03-01)

Mono‐TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study
by: Xue Yin, et al.
Published: (2025-03-01)

Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma
by: Xiangyong Hao, et al.
Published: (2025-08-01)

Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy
by: Cheng Xu, et al.
Published: (2025-07-01)

Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study
by: Qi-Yu Chi, et al.
Published: (2025-07-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Constructions and Properties for a Finite-Dimensional Modular Lie Superalgebra Kn,m
by: Dan Mao, et al.
Published: (2021-01-01)

N.V. Gogol and K.N. Leontiev: Recurrence of Westernism in “Conservative” Criticism
by: Igor’ A. Vinogradov
Published: (2022-06-01)